Potential Therapeutic Use of PPARγ‐Programed Human Monocyte‐Derived Dendritic Cells in Cancer Vaccination Therapy
Authors:
Open Access
- 1 January 2008
- journal article
- review article
- Published by Wiley in PPAR Research
- Vol. 2008 (1) , 473804
Abstract
Dendritic cells (DCs) can regulate all elements of the immune system, and therefore are an ideal target for vaccination. During the last two decades, as a result of extensive research, DCs became the primary target of antitumor vaccination as well. A critical issue of antitumor vaccination is the phenotype of the dendritic cell used. It has been recently shown that several nuclear hormone receptors, and amongst them the lipid‐activated nuclear receptor and peroxisome proliferator‐activated receptor gamma (PPARγ), have important roles in effecting the immunophenotype of human dendritic cells. It regulates primarily lipid metabolism and via this it influences the immunophenotype of DCs by altering lipid antigen uptake, presentation, and also other immune functions. In this review, we summarize the principles of antitumor vaccination strategies and present our hypothesis on how PPARγ‐regulated processes might be involved and could be exploited in the design of vaccination strategies.Keywords
Funding Information
- National Research and Technology Office (RET-06/2004, NK72730)
- Hungarian Scientific Research Fund (RET-06/2004, NK72730)
This publication has 75 references indexed in Scilit:
- Tumor-specific Th17-polarized cells eradicate large established melanomaBlood, 2008
- Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional responseCancer Letters, 2007
- DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypesProceedings of the National Academy of Sciences, 2007
- A Phase I Study ofIn vitroExpanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung CancerClinical Cancer Research, 2006
- PPARγ controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cellsJournal of Experimental Medicine, 2006
- Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsBlood, 2006
- Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppressionImmunology, 2006
- Expression of human DEC-205 (CD205) multilectin receptor on leukocytesInternational Immunology, 2006
- Peroxisome proliferator‐activated receptor γ activators inhibit interleukin‐12 production in murine dendritic cellsFEBS Letters, 2000
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994